CD274 and neoplasm: This can be explained by the fact that the OS benefit from pembrolizumab is related to the density of PD-L1 expression in the tumor,[21] which may be higher in the tumor cells of the study showed their special effect, and even the mutational burden can determine the response to the second-line therapy using pembrolizumab.[18] The time to respond is similar between therapies, so the objective response rate suggests that clinicians may consider either therapy for patients with advanced gastroesophageal cancer.